When Jean Shipos survived a recurrence of ovarian cancer in 2003, she and her daughter vowed to raise awareness of the disease. They got involved with a local run/walk, organizing … Continued
In a paper published on June 30, 2011 in the journal Nature, researchers working as part of The Cancer Genome Atlas (TCGA) Research Network report that they have created a … Continued
Kelly Smith founded the Ovarian Cancer Alliance of North Florida while she was on spring break from college one year. Based in Tallahassee, this Partner Member focuses on younger women, … Continued
Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.
Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.
Most survivors of gynecologic cancers have menopausal symptoms, and at least one in four takes replacement hormones, results of the first study of its kind showed.
Developers of a genetic-susceptibility test for ovarian cancer might have jumped the gun, according to an OCRF-funded research consortium that found no association between a KRAS mutation and risk of the cancer.
Cancer recurrence and death occurred significantly more often in ovarian cancer patients treated with erythropoietin-stimulating agents (ESAs), data from a retrospective cohort review showed.
Almost half of patients with heavily pretreated ovarian cancer benefited from an investigational PARP inhibitor, results of a phase I study showed.
Changes in expression of a microRNA showed potential for predicting response to the angiogenesis inhibitor bevacizumab (Avastin) in recurrent serous ovarian cancer, according to results of a small study reported here.
Most older patients with ovarian cancer may receive care that doesn't measure up to national standards, according to an analysis of a National Cancer Institute (NCI) database and Medicare claims data.
(Updated February 2017) Noting with equal measures of amazement and pride that “Stand-up for Madeline and OCRFA” had its 15th Anniversary on May 16, 2016, John Hansbury lovingly observes that … Continued
Get email updates about research news, action alerts, and ways to join the fight.
